Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nevirapine

FDA-approved product (tablet, oral), marketed as Nevirapine, Viramune, Viramune Xr.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Nevirapine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Non-nucleoside reverse transcriptase inhibitors
FDA pharmacologic class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AG01

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli49.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Nevirapine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nevirapine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine

    NCT00002381

    Registered record
    Registry ID
    NCT00002381
    Conditions
    HIV Infections
    Interventions
    Nelfinavir mesylate; Nevirapine; Stavudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNelfinavir mesylate; Nevirapine; Stavudine
    PhasePhase 1
    Registry statusCompleted

  • The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors

    NCT00002418

    Registered record
    Registry ID
    NCT00002418
    Conditions
    HIV Infections
    Interventions
    Emivirine; Hydroxyurea; Nevirapine; Stavudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionEmivirine; Hydroxyurea; Nevirapine; Stavudine +1 more
    PhasePhase 2
    Registry statusTerminated

  • Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen

    NCT00014937

    Registered record
    Registry ID
    NCT00014937
    Conditions
    HIV Infections
    Interventions
    lopinavir/ritonavir; lamivudine/zidovudine; efavirenz; lamivudine; stavudine; zidovudine; didanosine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionlopinavir/ritonavir; lamivudine/zidovudine; efavirenz; lamivudine +3 more
    PhaseNot applicable
    Registry statusCompleted

  • Changing to Nonprotease Inhibitor Treatment to Improve Side Effects

    NCT00021463

    Registered record
    Registry ID
    NCT00021463
    Conditions
    HIV Infections; Lipodystrophy
    Interventions
    Abacavir sulfate, Lamivudine and Zidovudine; Abacavir sulfate; Efavirenz; Nevirapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    342

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Lipodystrophy
    InterventionAbacavir sulfate, Lamivudine and Zidovudine; Abacavir sulfate; Efavirenz; Nevirapine
    PhasePhase 2
    Registry statusCompleted

  • Three Month Course of Anti-HIV Medications for People Recently Infected With HIV

    NCT00087464

    Registered record
    Registry ID
    NCT00087464
    Conditions
    HIV Infections
    Interventions
    Emtricitabine; Nevirapine; Tenofovir disoproxil fumarate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionEmtricitabine; Nevirapine; Tenofovir disoproxil fumarate
    PhaseNot applicable
    Registry statusWithdrawn